Overall survival in subjects receiving test treatments [ Time Frame: Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Adverse events in each treatment arm treatment regimen [ Time Frame: Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years ] [ Designated as safety issue: Yes ]

Have histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required, mixed histology is not allowed; subjects must have metastatic disease

2nd line, 3rd line or greater

At least 18 years of age

ECOG of 0 or 1

Anticipated life expectancy >12 weeks

For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormone implants) must be used throughout the study period and for 28 days after their final vaccine administration. (A barrier method of contraception must be employed by all subjects [male and female], regardless of other methods.)

Have adequate organ function as defined by specified laboratory values

Exclusion Criteria:

Allergy to both penicillin & sulfa or suspected hypersensitivity to GM-CSF, dimethyl sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the therapy options

Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment

Have any evidence of hepatic cirrhosis or clinical or radiographic ascites

Have prosthetic heart valves, major implant or device placed in the last 12 months or history of infection with implant/device that cannot be easily removed

Unable to avoid close contact with another individual known to be at high risk of listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during the course of CRS-207 treatment until completion of antibiotic regimen

Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02004262